Business briefing |
Regulatory briefing |
Regulatory reports |
Regulatory trackers |
Regulatory alerts roundup |
The Food and Drug Administration (FDA) rejected applications to use hemp extract as a dietary supplement.
Here are the conclusions we have attracted. CBD-Intel will continue to work on providing answers to the various questions that have arisen.
Blog | Policy and politics | US federal regulation
Signup for our newsletter and keep an eye on the latest news!
You’ve been successfully subscribed to our newsletter!
By signing up you agree to our Terms and Conditions
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.
To find out more, please visit About CBD-Intel.
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.
By signing up you agree to our Terms and Conditions Please note trial access may take up to 24 hours to be granted as access must be qualified by a member of the CBD-Intel team.